/
Integra LifeSciences Holdings Corporation is a global medical technology company dedicated to restoring lives. We are advancing transformational care through impactful innovation and our portfolio of highly differentiated technologies is trusted by healthcare professionals to deliver transformative care.
$19.10
$0.16 (-0.81%)
Live · 05:19 PM
The business is unprofitable at the operating level (-30.17% margin). The thesis depends entirely on whether and when it reaches sustainable profitability.
Revenue growth slowed to 1.5%, essentially flat. Margins also contracted 31.9pp. This is a business that needs a catalyst.
Free cash flow declined 224% versus the prior year, cash generation momentum has weakened. ROIC dropped from 0.89% to -17.58%, capital efficiency is deteriorating.
Based on TTM earnings · Diluted shares
Profitability & Returns
Revenue (TTM)
$1.64B
▲ +1.5% YoY
Net Income (TTM)
-$496M
▼ -7337.7% YoY
Op. Margin
-28.36%
▼ -31.9pp YoY
ROIC
-18.93%
▼ -18.5pp YoY
Cash Flow & Balance Sheet
FCF (TTM)
$4M
▼ -224.4% YoY
Op. Cash Flow (TTM)
$71M
▼ -61.1% YoY
Net Debt
$625M
Cash & Equiv.
$266M
5Y CAGR: +3.6%
Continue Research
Integra LifeSciences Holdings (IART) trades above a two-stage DCF intrinsic value of about $-7.21 per share, so at $19.10 the stock looks overvalued (137.8% above estimated intrinsic value). A high multiple is not the same as overvalued: fast-growing, high-quality businesses can deserve a premium. See the general approach in how to tell if a stock is overvalued.
On quality, Integra LifeSciences Holdings scores 16/100 on Intrinsiqq's quality scorecard (a lower-quality business on these measures), weighing growth, margins, returns on capital, share count, and balance-sheet strength. All figures are computed from SEC filings; read the full methodology. This is analysis, not investment advice.
Intrinsiqq's two-stage DCF estimates an intrinsic value of about $-7.21 per share for IART, projecting its recent free cash flow forward with a growth rate that fades toward a long-run rate and discounting it back to today. Applying a 25% margin of safety gives a more conservative fair-value entry around $-5.41. At today's $19.10, that puts the stock about 137.8% above estimated intrinsic value. The result is sensitive to the growth and discount-rate inputs, so it is best to run conservative, base and optimistic cases. You can adjust all of them yourself with the sliders on the DCF tab.
Integra LifeSciences Holdings scores 16 out of 100 on Intrinsiqq's quality score, a weighted blend of 7 metrics each scored 0 to 100, which makes it a lower-quality business on these measures. Recent fundamentals include a -28.4% operating margin and a -18.9% return on invested capital. The score weighs revenue and free-cash-flow growth, operating margins, return on invested capital, share-count change, and balance-sheet strength, all computed from SEC filings, not opinion. Because valuation only means something relative to quality, the full metric-by-metric breakdown is on the quality scorecard.
That depends on valuation and quality together, not either alone. IART currently trades above its estimated intrinsic value and scores 16/100 on quality (lower-quality). A cheap price is only a bargain if the business is durable, and a premium can be justified by genuine quality, so the two questions, "is it cheap?" and "is it good?", only make sense side by side. Read the valuation against the quality scorecard, run the DCF on your own assumptions, and decide for yourself. This is analysis from SEC filings, not investment advice.